A recent study found over 18% of patients with relapsed or refractory multiple myeloma treated with a proteasome inhibitor were faced with cardiovascular adverse events.


Survivors of Hodgkin lymphoma with a family history of cancer have a 1.3-fold higher risk of developing a second cancer, according to research published in the Journal of Clinical Oncology (May 2017;35[14]:1584-1590).


Related Content

Read More

Subscribe to Multiple Myeloma